Acute lymphoblastic leukemia with multiple cytogenetic abnormalities secondary to treatment of Ewing's sarcoma

Leukemia Research

Volumn 23, Issue 6, 1999, Pages 593-596

  Al Homaidhi, A M ^a   Patterson, B ^a   Rubin, S ^b   Lipton, J H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b MONCTON HOSPITAL   (Canada)

Author keywords

Acute lymphoblastic leukemia; Ewing's sarcoma; Secondary malignancy

Indexed keywords

ANTIINFECTIVE AGENT; ASPARAGINASE; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHROMOSOME 5; CHROMOSOME 7; CYTOGENETICS; EWING SARCOMA; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MUSCLE ATROPHY; ORAL DRUG ADMINISTRATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION; WOUND INFECTION;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; COMBINED MODALITY THERAPY; HUMANS; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; MALE; RADIOTHERAPY; SARCOMA, EWING'S;

EID: 0033037899     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(98)00193-3     Document Type: Article

References (23)

1. Smith M.A., McCaffrey R.P., Karp J.E. The secondary leukemias: challenges and research directions. J. Nat. Cancer Instit. 88:1996;407.
2. Kaldor J.E., Day N.E., Clarke E.A., Van Leeuwen F.E., Henry-Amar M., Fiorentino M.V. et al. Leukemia following Hodgkin's disease. New Eng. J. Med. 322:1990;7.
3. Rowley J., Golomb H., Vardiman J. Non-random chromosomal abnormalities in acute nonlymphoblastic lymphoma patients treated for Hodgkin's disease. Blood. 50:1997;759.
4. Hawkins M.M., Wilson L.M.K., Stovall M.A., Marsden H.B., Potok M.H.N., Kingston J.E., Chessells J.M. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukemia after childhood cancer. Br. Med. J. 304:1992;951.
5. Kapoor G., Bajpai S., Nair C.N., Badrinath Y., Gladstone B., Advani S.H. CALLA positive acute lymphoblastic leukemia after Etoposide-based therapy for Ewing's sarcoma. Leuk. Res. 19:1995;771.
6. Levine E.G., Bloomfield C.D. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin. Oncol. 19:1992;47.
7. Secker-Walker L.M., Stewart E.L., Todd A. Acute lymphoblastic leukemia with t(4;11) following neuroblastoma: a late effect of treatment. Med. Pediat. Oncol. 13:1985;48.
8. Nichols C.R., Breeden E.S., Loehrer P.J., Williams S.D., Einhorn L.H. Secondary leukemia associated with a conventional dose of Etoposide: review of serial germ cell tumor protocols. J. Nat. Cancer Inst. 85:1993;36.
9. Smithson W., Burgert E.O., Childs D., Hoagland H.C. Acute myelomonocytic leukemia after irradiation and chemotherapy for Ewing's sarcoma. Mayo Clin. Proc. 53:1978;757.
10. Link M.P., Donaldson S.S., Kempson R.L., Wilbur J.R., Glades B.E. et al. Acute nonlymphocytic leukemia developing during the course of Ewing's sarcoma. Med. Pediat. Oncol. 12:1984;194.
11. Smith L.M., Cox R.S., Donaldson S.S. Second cancers in long-term survivors of Ewing's sarcoma. Clin. Ortho. Relat. Res. 274:1992;275.
12. Ellis M., Ravid M., Lishner M. A comparative analysis of alkylating agents and epipodophyllotoxin-related leukemias. Leuk. Lymph. 11:1993;9.
13. Mitelman F., Brandt L., Nilsson P. Relation among occupational exposure to potential mutagenic/carcinogenic agents, clinical findings, and bone marrow chromosomes in acute nonlymphoblastic leukemia. Blood. 52:1978;1229.
14. Golomb H.M., Alimena G., Rowley J.D., Vardiman J.W., Testa J.R., Sovik S. Correlation of occupation and karyotype in adult acute nonlymphoblastic leukemia. Blood. 60:1982;404.
15. Pederson-Bjergaard J., Rowley J.D. The balanced and unbalanced chromosomal aberrations of acute myeloid leukemia may develop in different ways and may contribute to malignant transformation. Blood. 83:1994;2780.
16. Rubin C.M., Arthur D.C., Woods W.G., Lange B.J., Nowell P.C., Rowley J.D. et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia in children: correlation between chromosomal abnormalities and prior therapy. Blood. 78:1991;2982.
17. Gill Super H.J., McCabe N.R., Thirman M.J., Larson R.A., LaBeau M.M., Pedersen Bjergaard J., Philip P., Diaz M.O., Rowley J.D. Rearrangement of MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood. 823:1993;705.
18. Pui C.H., Ribeiro R.C., Hancock M.L., Rivera G.K., Evans W.E., Raimondi S.C., Head D.R., Behm F.G., Mahmoud M.H., Sandlund J.T., Crist W.M. Acute myeloid leukemia in children treated with etoposide for acute lymphoblastic leukemia. New. Eng. J. Med. 325:1991;1682.
19. Hunger S.P., Thachuk D.C., Amylon M.D., Link M.P., Carroll A.J., Wellborn J.L., Willman C.L., Cleary M.L. HRX involvement in de novo and secondary leukemia with diverse chromosome 11q23 abnormality. Blood. 81:1993;3197.
20. Strong L.C., Herson J., Osborne B.M., Sutow W.W. Risk of radiation-related subsequent malignant tumors in survivors of Ewing's sarcoma. J. Nat. Cancer Inst. 62:1979;1401.
21. Greene M.H., Glaubiger D.L., Mend G.D., Fraumeni J.F. Jr. Subsequent cancer in patients with Ewing's sarcoma. Cancer. Treat. Rep. 63:1979;2043.
22. Robertson P.B., Nieman R.S., Worapongpaiboons J.K., Orazi A. 013(CD99) positivity in haematologic proliferations correlates with TdT positivity. Mod. Pathol. 10:1997;277.
23. Dorfman D.M., Kraus M., Perez-Atayde A.R., Barnhill R.L., Pinkus G.S., Granter M.D. CD99 (p30/32M1C2) Immunoreactivity in the diagnosis of leukemia cutis. Mod. Pathol. 10:1997;283.